Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
AIMS: To report the rate of intraocular pressure (IOP) elevation associated with repeated intravitreal injections of antivascular endothelial growth factor (VEGF) agents and to determine if a pre-existing diagnosis of glaucoma is a risk factor for this phenomenon. METHODS: The charts of 215 eyes undergoing intravitreal injection with anti-VEGF agents for wet age-related macular degeneration (AMD) were retrospectively examined with respect to frequency of injections, number of injections and changes in IOP. Data were analysed independently for two groups (1) pre-existing glaucoma and (2) no history of glaucoma. RESULTS: Of the 215 eyes receiving injections with bevacizumab and/or ranibizumab, 6% (n=13) had sustained IOP elevation requiring medical or laser interventions. Of the eyes receiving only bevacizumab, 9.9% (10/101) had sustained elevated IOP, while 3.1% (3/96) of eyes receiving only ranibizumab experienced increases (p=0.049). Patients with pre-existing glaucoma experienced higher rates of elevated IOP when compared with patients without pre-existing glaucoma (33% vs 3.1% respectively; p<0.001). The glaucoma subgroup had a lower median number of injections (6; interquartile range 5-10) compared with the non-glaucoma group (9.5; interquartile range 6-13.7; p=0.031). CONCLUSIONS: The incidence of sustained elevated IOP in patients receiving intravitreal anti-VEGF injections is significant. Additionally, these data suggest the possibility of a heightened risk for further elevation of IOP in patients with pre-existing glaucoma who receive either bevacizumab or ranibizumab. Prospective studies are needed to verify these results and better understand the implications of these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Bressler, S. B. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.045 · Cited by 205 · cited 1×
“2 Inhibition of VEGF, in particular with ranibizumab (Lucentis; Genentech, South San Francisco, California) and bevacizumab (Avastin; Genentech, Inc), has been found to be an effective treatment for these conditions.(3) Bevacizumab is a recombinant humanised monoclonal IgG antibody that acts by inhibiting VEGF, while…”
Background
Cited by
Ghasemi Falavarjani, K., & Nguyen, Q. D. (2013) · Eye · doi:10.1038/eye.2013.107 · Cited by 982
INTRAVITREAL INJECTION TECHNIQUE AND MONITORING: Updated Guidelines of an Expert Panel
Avery, R. L., Bakri, S. J., Blumenkranz, M. S., Brucker, A. J., Cunningham, E. T., D'Amico, D. J., Dugel, P. U., Flynn, H. W., Freund, K. B., Haller, J. A., et al. (2014) · Retina · doi:10.1097/iae.0000000000000399 · Cited by 266
Liu, L., Ammar, D. A., Ross, L. A., Mandava, N., Kahook, M. Y., & Carpenter, J. F. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6431 · Cited by 199
Self-citation
Metadata
- Authors
- Good, T. J., Kimura, A. E., Mandava, N., & Kahook, M. Y.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2010-08-11
- Volume
- 95
- Issue
- 8
- Pages
- 1111-1114
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W2007317284
- Cited by
- 245
- References
- 2
- FWCI
- 14.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. https://app.cochat.ai/papers/10.1136/bjo.2010.180729
- The paper
- Good, T. J., Kimura, A. E., Mandava, N., & Kahook, M. Y. (2011). Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. British Journal of Ophthalmology. https://doi.org/10.1136/bjo.2010.180729
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.